Double J Stents and Reno-Ureteral Lithiasis: Dynamic Changes in Management during the COVID-19 Pandemic.

Publication date: Oct 25, 2023

To provide an evidence-based review of the use of ureteral stents in managing reno-ureteral lithiasis during the COVID-19 pandemic. A literature search was conducted between 2020 and 2023 using the PubMed and SCOPUS databases. As a part of the search query, we entered “ureteral stents” OR “double J stent” AND “renal colic” OR “ureteral obstruction” OR “reno-ureteral lithiasis” AND “COVID-19 Pandemic” OR “SARS-CoV-2 infection”. Patients with lithiasis should be categorized into low priority, intermediate priority, high priority, and emergency under the COVID-19 pandemic scenario to manage their delay and save resources, including healthcare professionals, beds, and ventilators. However, immediate interventions are necessary for individuals at risk of life-threatening septic complications. During the COVID-19 pandemic, the feasibility of conducting or resuming elective activity depended on local circumstances, the accessibility of beds and ventilators, and the execution of screening protocols. If lithiasis surgery is delayed, consequences and increased effort will be inevitable. It is possible that teleconsultation could help guide these patients and cut down on unnecessary visits and exposure. COVID-19 has shifted treatment options for urinary stones, with ureteral stents being a safe, efficient, and cost-effective option for managing urolithiasis. Decompression is essential in emergency situations, while ureteral stents reduce the risk of infection and hospital visits.

Open Access PDF

Concepts Keywords
Basel COVID-19
Conducting double J stent
Pandemic ureteral obstruction
Reno urolithiasis
Ureteral

Semantics

Type Source Name
disease MESH Lithiasis
disease MESH COVID-19 Pandemic
disease MESH ureteral obstruction
pathway REACTOME SARS-CoV-2 Infection
disease MESH emergency
disease MESH complications
disease VO efficient
disease VO effective
disease MESH urolithiasis
disease MESH infection
disease MESH kidney stone
disease MESH causes
disease VO time
disease VO organization
drug DRUGBANK Coenzyme M
disease MESH respiratory failure
disease VO organ
disease IDO contagiousness
disease IDO intervention
disease MESH shock
disease MESH infected hydronephrosis
disease MESH sepsis
disease VO effectiveness
disease MESH hematuria
disease MESH urinary tract infection
drug DRUGBANK Isoxaflutole
disease MESH postoperative complications
disease IDO country
disease VO USA
disease MESH morbidity
disease MESH pyelonephritis
disease MESH bacteremia
disease MESH death
disease IDO process
disease IDO production
disease MESH nephrolithiasis
disease VO frequency
drug DRUGBANK Platinum
disease VO volume
disease MESH clinical progression
disease MESH solitary kidney
disease MESH ureteral calculi
disease MESH critically ill
disease VO Thing
disease MESH kidney failure
disease MESH strictures
disease MESH septic shock
disease MESH syndrome
disease MESH abscesses
disease VO population
drug DRUGBANK Creatinine
disease IDO blood
disease MESH hydronephrosis
disease MESH recurrent infections
disease MESH Urologic Diseases
disease MESH pneumonia
disease VO Pal
disease MESH Phimosis

Original Article

(Visited 1 times, 1 visits today)